home / stock / nurpf / nurpf short
Short Information | Neuren Pharms Ltd Ord (OTCMKTS:NURPF)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 6,162 |
Total Actual Volume | 9,915 |
Short Trends | |
---|---|
Cover Days | 2 |
Short Days | 17 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 308 |
Average Short Percentage | 83.31% |
Is there a NURPF Short Squeeze or Breakout about to happen?
See the NURPF Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
04-25-2024 | $12.51 | $12.51 | $12.51 | $12.51 | 600 | 600 | 100% |
04-15-2024 | $12.66 | $12.53 | $12.66 | $12.53 | 1,000 | 500 | 50% |
03-26-2024 | $13.45 | $13.45 | $13.45 | $13.45 | 100 | 100 | 100% |
03-19-2024 | $13.405 | $13.405 | $13.405 | $13.405 | 100 | 100 | 100% |
03-07-2024 | $0 | $12.22 | $0 | $0 | 50 | 50 | 100% |
02-28-2024 | $12.5 | $12.5 | $12.5 | $12.5 | 320 | 320 | 100% |
02-26-2024 | $13.6 | $13.88 | $13.88 | $13.6 | 200 | 200 | 100% |
02-16-2024 | $13.35 | $12.99 | $13.35 | $12.775 | 1,730 | 430 | 24.86% |
01-31-2024 | $0 | $15.56 | $0 | $0 | 20 | 20 | 100% |
01-29-2024 | $0 | $15.56 | $0 | $0 | 20 | 20 | 100% |
01-26-2024 | $15.86 | $15.56 | $15.86 | $15.56 | 370 | 360 | 97.3% |
01-25-2024 | $15.65 | $15.65 | $15.65 | $15.65 | 246 | 240 | 97.56% |
01-18-2024 | $0 | $15.465 | $0 | $0 | 100 | 75 | 75% |
01-09-2024 | $15.97 | $15.715 | $15.97 | $15.715 | 1,400 | 1,400 | 100% |
01-08-2024 | $0 | $16.66 | $0 | $0 | 50 | 50 | 100% |
01-05-2024 | $16.66 | $16.66 | $16.66 | $16.62 | 1,650 | 650 | 39.39% |
01-04-2024 | $16.6231 | $16.6231 | $16.6231 | $16.6231 | 250 | 250 | 100% |
01-03-2024 | $16.425 | $16.425 | $16.425 | $16.425 | 647 | 147 | 22.72% |
12-28-2023 | $17.205 | $17.165 | $17.205 | $17.165 | 1,012 | 600 | 59.29% |
12-27-2023 | $0 | $15.31 | $0 | $0 | 50 | 50 | 100% |
News, Short Squeeze, Breakout and More Instantly...
Neuren Pharms Ltd Ord Company Name:
NURPF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Neuren Pharmaceuticals Ltd (ASX:NEU) CEO Jon Pilcher speaks with Proactive following the news that its North America partner Acadia Pharmaceuticals has received US Food and Drug Administration approval of DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adult an...